Logo image of DLHC

DLH HOLDINGS CORP (DLHC) Stock Fundamental Analysis

NASDAQ:DLHC - US23335Q1004 - Common Stock

5.52 USD
+0.01 (+0.18%)
Last: 8/26/2025, 2:03:56 PM
5.5 USD
-0.02 (-0.36%)
After Hours: 8/19/2025, 8:00:01 PM
Fundamental Rating

3

Overall DLHC gets a fundamental rating of 3 out of 10. We evaluated DLHC against 81 industry peers in the Professional Services industry. DLHC has a medium profitability rating, but doesn't score so well on its financial health evaluation. DLHC is valued correctly, but it does not seem to be growing.


Dividend Valuation Growth Profitability Health

4

1. Profitability

1.1 Basic Checks

DLHC had positive earnings in the past year.
DLHC had a positive operating cash flow in the past year.
In the past 5 years DLHC has always been profitable.
In the past 5 years DLHC always reported a positive cash flow from operatings.
DLHC Yearly Net Income VS EBIT VS OCF VS FCFDLHC Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M

1.2 Ratios

DLHC's Return On Assets of 1.54% is in line compared to the rest of the industry. DLHC outperforms 43.21% of its industry peers.
DLHC has a Return On Equity of 4.03%. This is comparable to the rest of the industry: DLHC outperforms 46.91% of its industry peers.
DLHC has a Return On Invested Capital (6.53%) which is in line with its industry peers.
The Average Return On Invested Capital over the past 3 years for DLHC is in line with the industry average of 12.68%.
The last Return On Invested Capital (6.53%) for DLHC is well below the 3 year average (11.90%), which needs to be investigated, but indicates that DLHC had better years and this may not be a problem.
Industry RankSector Rank
ROA 1.54%
ROE 4.03%
ROIC 6.53%
ROA(3y)5.52%
ROA(5y)5.12%
ROE(3y)11.15%
ROE(5y)12.44%
ROIC(3y)11.9%
ROIC(5y)11.03%
DLHC Yearly ROA, ROE, ROICDLHC Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10 20 30

1.3 Margins

DLHC has a Profit Margin (1.28%) which is in line with its industry peers.
In the last couple of years the Profit Margin of DLHC has declined.
DLHC has a Operating Margin of 5.81%. This is comparable to the rest of the industry: DLHC outperforms 53.09% of its industry peers.
DLHC's Operating Margin has declined in the last couple of years.
DLHC's Gross Margin of 19.88% is on the low side compared to the rest of the industry. DLHC is outperformed by 76.54% of its industry peers.
In the last couple of years the Gross Margin of DLHC has declined.
Industry RankSector Rank
OM 5.81%
PM (TTM) 1.28%
GM 19.88%
OM growth 3Y-5.33%
OM growth 5Y-2.34%
PM growth 3Y-23.18%
PM growth 5Y-10.77%
GM growth 3Y-1.6%
GM growth 5Y-2.24%
DLHC Yearly Profit, Operating, Gross MarginsDLHC Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5 10 15 20

2

2. Health

2.1 Basic Checks

The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so DLHC is still creating some value.
The number of shares outstanding for DLHC has been increased compared to 1 year ago.
The number of shares outstanding for DLHC has been increased compared to 5 years ago.
DLHC has a better debt/assets ratio than last year.
DLHC Yearly Shares OutstandingDLHC Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M 8M 10M
DLHC Yearly Total Debt VS Total AssetsDLHC Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

DLHC has an Altman-Z score of 1.76. This is a bad value and indicates that DLHC is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of 1.76, DLHC is doing worse than 70.37% of the companies in the same industry.
The Debt to FCF ratio of DLHC is 5.61, which is a neutral value as it means it would take DLHC, 5.61 years of fcf income to pay off all of its debts.
DLHC has a Debt to FCF ratio (5.61) which is comparable to the rest of the industry.
A Debt/Equity ratio of 1.09 is on the high side and indicates that DLHC has dependencies on debt financing.
With a Debt to Equity ratio value of 1.09, DLHC is not doing good in the industry: 72.84% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 1.09
Debt/FCF 5.61
Altman-Z 1.76
ROIC/WACC0.65
WACC10.07%
DLHC Yearly LT Debt VS Equity VS FCFDLHC Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

2.3 Liquidity

A Current Ratio of 1.09 indicates that DLHC should not have too much problems paying its short term obligations.
DLHC has a Current ratio of 1.09. This is in the lower half of the industry: DLHC underperforms 69.14% of its industry peers.
DLHC has a Quick Ratio of 1.09. This is a normal value and indicates that DLHC is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 1.09, DLHC is doing worse than 69.14% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.09
Quick Ratio 1.09
DLHC Yearly Current Assets VS Current LiabilitesDLHC Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

2

3. Growth

3.1 Past

DLHC shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -37.25%.
DLHC shows a small growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 1.22% yearly.
The Revenue for DLHC has decreased by -10.30% in the past year. This is quite bad
The Revenue has been growing by 19.81% on average over the past years. This is quite good.
EPS 1Y (TTM)-37.25%
EPS 3Y-11.67%
EPS 5Y1.22%
EPS Q2Q%-75%
Revenue 1Y (TTM)-10.3%
Revenue growth 3Y17.18%
Revenue growth 5Y19.81%
Sales Q2Q%-17.23%

3.2 Future

The Earnings Per Share is expected to decrease by -59.37% on average over the next years. This is quite bad
The Revenue is expected to decrease by -21.79% on average over the next years. This is quite bad
EPS Next Y-66%
EPS Next 2Y-59.37%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year-13.41%
Revenue Next 2Y-21.79%
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

The EPS growth rate is decreasing: in the next years the growth will be less than in the last years.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
DLHC Yearly Revenue VS EstimatesDLHC Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 100M 200M 300M 400M
DLHC Yearly EPS VS EstimatesDLHC Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 0 0.5 1 1.5

4

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings ratio is 17.25, which indicates a rather expensive current valuation of DLHC.
Compared to the rest of the industry, the Price/Earnings ratio of DLHC indicates a somewhat cheap valuation: DLHC is cheaper than 62.96% of the companies listed in the same industry.
When comparing the Price/Earnings ratio of DLHC to the average of the S&P500 Index (27.03), we can say DLHC is valued slightly cheaper.
The Forward Price/Earnings Ratio is negative for DLHC. No positive earnings are expected for the next year.
Industry RankSector Rank
PE 17.25
Fwd PE N/A
DLHC Price Earnings VS Forward Price EarningsDLHC Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20 -20

4.2 Price Multiples

Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of DLHC indicates a rather cheap valuation: DLHC is cheaper than 92.59% of the companies listed in the same industry.
Based on the Price/Free Cash Flow ratio, DLHC is valued cheaper than 98.77% of the companies in the same industry.
Industry RankSector Rank
P/FCF 3.23
EV/EBITDA 5.73
DLHC Per share dataDLHC EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 20

4.3 Compensation for Growth

A cheap valuation may be justified as DLHC's earnings are expected to decrease with -59.37% in the coming years.
PEG (NY)N/A
PEG (5Y)14.14
EPS Next 2Y-59.37%
EPS Next 3YN/A

0

5. Dividend

5.1 Amount

DLHC does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

DLH HOLDINGS CORP

NASDAQ:DLHC (8/26/2025, 2:03:56 PM)

After market: 5.5 -0.02 (-0.36%)

5.52

+0.01 (+0.18%)

Chartmill FA Rating
GICS SectorIndustrials
GICS IndustryGroupCommercial & Professional Services
GICS IndustryProfessional Services
Earnings (Last)08-06 2025-08-06/amc
Earnings (Next)12-02 2025-12-02/amc
Inst Owners72.98%
Inst Owner Change9.71%
Ins Owners13.55%
Ins Owner Change0%
Market Cap79.43M
Analysts82.86
Price Target10.2 (84.78%)
Short Float %0.91%
Short Ratio1.87
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-8.96%
Min EPS beat(2)-15.97%
Max EPS beat(2)-1.96%
EPS beat(4)2
Avg EPS beat(4)9.18%
Min EPS beat(4)-15.97%
Max EPS beat(4)42.6%
EPS beat(8)4
Avg EPS beat(8)3.31%
EPS beat(12)6
Avg EPS beat(12)0.33%
EPS beat(16)8
Avg EPS beat(16)2.25%
Revenue beat(2)0
Avg Revenue beat(2)-2.19%
Min Revenue beat(2)-2.82%
Max Revenue beat(2)-1.56%
Revenue beat(4)0
Avg Revenue beat(4)-4.76%
Min Revenue beat(4)-8.25%
Max Revenue beat(4)-1.56%
Revenue beat(8)1
Avg Revenue beat(8)-3.95%
Revenue beat(12)1
Avg Revenue beat(12)-4.15%
Revenue beat(16)3
Avg Revenue beat(16)-2.78%
PT rev (1m)0%
PT rev (3m)-33.33%
EPS NQ rev (1m)0%
EPS NQ rev (3m)111.77%
EPS NY rev (1m)-10.53%
EPS NY rev (3m)230.77%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)27.27%
Revenue NY rev (1m)-0.05%
Revenue NY rev (3m)8.11%
Valuation
Industry RankSector Rank
PE 17.25
Fwd PE N/A
P/S 0.22
P/FCF 3.23
P/OCF 3.18
P/B 0.7
P/tB N/A
EV/EBITDA 5.73
EPS(TTM)0.32
EY5.8%
EPS(NY)-0.28
Fwd EYN/A
FCF(TTM)1.71
FCFY30.94%
OCF(TTM)1.74
OCFY31.47%
SpS25
BVpS7.85
TBVpS-8.41
PEG (NY)N/A
PEG (5Y)14.14
Profitability
Industry RankSector Rank
ROA 1.54%
ROE 4.03%
ROCE 8.26%
ROIC 6.53%
ROICexc 6.53%
ROICexgc 87.8%
OM 5.81%
PM (TTM) 1.28%
GM 19.88%
FCFM 6.83%
ROA(3y)5.52%
ROA(5y)5.12%
ROE(3y)11.15%
ROE(5y)12.44%
ROIC(3y)11.9%
ROIC(5y)11.03%
ROICexc(3y)11.92%
ROICexc(5y)11.56%
ROICexgc(3y)141.18%
ROICexgc(5y)N/A
ROCE(3y)15.06%
ROCE(5y)13.96%
ROICexcg growth 3YN/A
ROICexcg growth 5Y-9.76%
ROICexc growth 3Y-17.62%
ROICexc growth 5Y-3.79%
OM growth 3Y-5.33%
OM growth 5Y-2.34%
PM growth 3Y-23.18%
PM growth 5Y-10.77%
GM growth 3Y-1.6%
GM growth 5Y-2.24%
F-Score7
Asset Turnover1.2
Health
Industry RankSector Rank
Debt/Equity 1.09
Debt/FCF 5.61
Debt/EBITDA 3.27
Cap/Depr 2.47%
Cap/Sales 0.12%
Interest Coverage 1.49
Cash Conversion 65.96%
Profit Quality 535.51%
Current Ratio 1.09
Quick Ratio 1.09
Altman-Z 1.76
F-Score7
WACC10.07%
ROIC/WACC0.65
Cap/Depr(3y)6.78%
Cap/Depr(5y)4.75%
Cap/Sales(3y)0.2%
Cap/Sales(5y)0.14%
Profit Quality(3y)812.14%
Profit Quality(5y)631.47%
High Growth Momentum
Growth
EPS 1Y (TTM)-37.25%
EPS 3Y-11.67%
EPS 5Y1.22%
EPS Q2Q%-75%
EPS Next Y-66%
EPS Next 2Y-59.37%
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-10.3%
Revenue growth 3Y17.18%
Revenue growth 5Y19.81%
Sales Q2Q%-17.23%
Revenue Next Year-13.41%
Revenue Next 2Y-21.79%
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-20.73%
EBIT growth 3Y10.94%
EBIT growth 5Y17.01%
EBIT Next Year46.92%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y24.2%
FCF growth 3Y-16.89%
FCF growth 5Y8.21%
OCF growth 1Y19.05%
OCF growth 3Y-16.07%
OCF growth 5Y8.4%